Pethidine hydrochloride veterinary-grade active pharmaceutical ingredient (API) is a synthetic phenylpiperidine derivative supplied for licensed manufacture of tablets, injections, capsules, powders, granules, premix, and aqueous solutions. The chemical identity is ethyl 1-methyl-4-phenylpiperidine-4-carboxylate hydrochloride, C₁₅H₂₁NO₂·HCl, CAS 50-13-5 for the hydrochloride salt and 57-42-1 for the free base. The molecular mass of the hydrochloride is 283.79 g/mol; the base has a molecular mass of 247.33 g/mol. The material is produced as a white or almost white crystalline powder that is freely soluble in water and soluble in ethanol. Pharmacologically, pethidine acts as a μ-opioid receptor agonist, with approximately 0.1–0.125 times the milligram potency of morphine sulfate in parenteral use. The substance is subject to international narcotics control under the Single Convention on Narcotic Drugs 1961 and is listed as a Schedule II controlled substance in the United States under the Controlled Substances Act. Because of this regulatory status, the veterinary-grade API is distributed only through controlled-substance licences, and manufacturing records, storage, and destruction must satisfy national security and diversion-control requirements.

The primary commercial designation is the pharmacopoeial salt form, pethidine hydrochloride, rather than a single equipment-specific model. Suppliers differentiate material by pharmacopoeial monograph, residual solvent profile, particle size distribution, and packaging configuration. The tertiary amine nitrogen of pethidine has an approximate pKa of 8.7, so aqueous formulations are maintained below pH 6.0 to keep the hydrochloride salt in solution and to reduce free-base precipitation. A 5% aqueous solution of the hydrochloride is typically adjusted to pH 3.5–6.0. These properties distinguish the product from morphine sulfate, which is a phenanthrene alkaloid salt, and from fentanyl, which is a phenylpiperidine but with substantially higher milligram potency and a different partition profile.

What Limits Direct Compression of a Freely Soluble Opioid Hydrochloride?

In solid dosage manufacture, the physicochemical profile of pethidine hydrochloride introduces flow, segregation, and content-uniformity constraints rather than solubility constraints. Because the hydrochloride is freely soluble in water, dissolution from tablets and capsules is rarely the limiting variable; instead, blend homogeneity and API particle size control dominate. For direct compression, a laser diffraction Dv50 between 50 µm and 150 µm is typically targeted when the API is blended with spray-dried lactose or microcrystalline cellulose in a V-blender or bin blender. Powder flow is assessed by USP 1174 angle of repose and compressibility index; high fines loadings below 50 µm can reduce flow and require forced feed on a rotary tablet press. Content uniformity testing by USP 905 is mandatory for tablets containing the low-dose active ingredient, and sampling plans usually include 10 or more locations across batch discharge. Wet granulation in a high-shear granulator allows finer API grades because the binder liquid densifies the mass, but residual moisture must be held below the loss-on-drying limit before compression. The operating envelope for common solid-dosage unit operations is summarised in Table 1.

Stability Boundaries in Aqueous and Solid-State Processing

Pethidine is an ethyl ester, and the hydrolysis product 1-methyl-4-phenylpiperidine-4-carboxylic acid must be controlled as a related substance in both solid and liquid formulations. Hydrolytic degradation is accelerated under alkaline conditions, which is one reason aqueous formulations are maintained in the acidic range. N-demethylation to norpethidine is primarily metabolic, but oxidative degradation during storage or thermal processing can contribute to specified impurity formation. Pharmacopoeial monographs therefore control related substances by HPLC with individual and total acceptance limits. The dry hydrochloride salt is stored in tightly closed, light-resistant containers at controlled room temperature; bulk storage at uncontrolled humidity may require pre-drying before direct compression or capsule filling. Residues and degraded batches are handled as controlled waste because the active moiety remains subject to narcotics control.

Injectable processing requires stainless-steel mixing vessels, pH adjustment with hydrochloric acid, and sterilising-grade filtration through a 0.22 µm membrane. Solutions are filled under nitrogen where oxygen sensitivity has been demonstrated, and terminal moist-heat sterilisation is considered only after forced-degradation and container-closure validation. Published data for pethidine hydrochloride aqueous terminal sterilisation across all rubber stopper and glass combinations are limited; therefore, each formulation requires an ICH Q1A(R2) forced-degradation study covering acid, base, oxidative, thermal, and photolytic conditions. Alkaline diluents and certain buffered parenteral solutions should be avoided because pH elevation above 6.0 can initiate precipitation of the free base.

For tablets and capsules, pethidine hydrochloride is usually processed at low to moderate drug loadings. Direct compression blends require geometric dilution when the API fraction is low, and scooping or extended blending times may increase segregation when the API and excipient particle size distributions differ. Capsules containing pethidine hydrochloride should be tested for dissolution using USP 711 apparatus conditions appropriate to the formulation, typically acidic media that reflect the freely soluble salt. Granulated products intended for sachets or powders require controlled particle size to ensure dose uniformity in animals of varying body mass. Premix manufacture for oral administration in feed is constrained by chain-of-custody and security requirements; a double-cone blender or ribbon blender is used with a carrier selected to resist density-driven segregation, and top-loading of fine API without geometric dilution is not recommended.

Quality control release for the API includes appearance, identification by infrared absorption spectrophotometry using Ph. Eur. 2.2.24, assay by HPLC, related substances, loss on drying by Ph. Eur. 2.2.32, sulfated ash, residual solvents according to ICH Q3C, and chloride identification. Batch-to-batch variance is monitored through control charts of assay, moisture, and particle size. Retention samples are stored in hermetic containers at 25 °C in the dark, and stability-indicating methods are used to distinguish hydrolytic and oxidative degradation products from process impurities.

When Veterinary Species Differences Require Dosing Precision

Compared with morphine sulfate, pethidine HCl has a shorter duration of action and a different adverse-effect profile in veterinary patients. The milligram potency of pethidine is approximately 0.1–0.125 relative to morphine when given parenterally to dogs; clinical effect typically lasts 2–4 h, against 4–6 h for morphine. Repeated administration or renal impairment is a defined clinical limit because the metabolite norpethidine accumulates and lowers the seizure threshold. Constant-rate infusion protocols are therefore discouraged or shortened. In cats, pethidine may produce less sedation than in dogs at equianalgesic doses, and in horses opioids can produce central nervous system excitation and increased locomotor activity, requiring dose-rate adjustment. Species-specific metabolic capacity and elimination pathways must be considered before including pethidine in a veterinary protocol. Comparative data for selected injectable opioids are provided in Table 2.

Formulation selection is dictated by the dosage form, the target species, and the controlled-substance containment class of the manufacturing site. Injectable solutions require pH control and sterilising filtration; tablets and capsules require blend uniformity and dissolution control; granules and powders for oral administration require particle size control and geometric dilution; premix operations require security-compliant sampling and carrier compatibility. The API is not appropriate for unrestricted feed-use formulations because of regulatory control, norpethidine risk, and the need for individual dose calculation in most veterinary indications. In each case, the manufacturing process must be validated to demonstrate batch-to-batch reproducibility, and controlled-substance reconciliation must meet national licensing obligations.